Company intelligence / Profile preview

CorAssist

Ownership: Private
Employees: ~14
Development stage: Phase 2

Overview

CorAssist is developing a first-in-class implantable medical device to treat diastolic heart failure, specifically targeting patients with heart failure with preserved ejection fraction. The company has started human clinical trials and has raised significant private financing to support its development. Its approach is unique as there are currently no other devices on the market specifically for this indication

Therapeutic areas: Cardiovascular
Modalities: Device (medical device/implantable device for heart failure)
Industry: Implantable Medical Devices

Drug pipeline

2 assets

CORolla

Phase 2

Indications: Heart failure with preserved ejection fraction

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on CorAssist.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CorAssist.

Explore the full profile